Key Points
- Bain Capital Life Sciences sold 2,000,000 Heartflow shares on Feb. 4 at $28.05 each for $56.1M, reducing its position by 16.07% to 10,448,158 shares (≈$293.1M).
- Heartflow stock jumped about 6.7%, opened at $27.74, and the company has a market cap of $2.36B with a trailing PE of -15.33 and a 1‑year range of $25.38–$41.22.
- Several institutions have built large new stakes (e.g., Wellington, Baillie Gifford, Vanguard), and analysts are mostly positive with a consensus Moderate Buy rating and a $38.50 average price target.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the company's stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total value of $56,100,000.00. Following the sale, the insider owned 10,448,158 shares in the company, valued at approximately $293,070,831.90. This represents a 16.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Heartflow Stock Up 6.7%
NASDAQ:HTFL opened at $27.74 on Friday. The company has a market capitalization of $2.36 billion and a PE ratio of -15.33. Heartflow, Inc. has a 1-year low of $25.38 and a 1-year high of $41.22. The firm has a fifty day moving average price of $30.33.
Institutional Trading of Heartflow
A number of institutional investors have recently modified their holdings of HTFL. Wellington Management Group LLP acquired a new position in Heartflow in the third quarter valued at about $164,263,000. Baillie Gifford & Co. bought a new stake in Heartflow during the third quarter worth $101,182,000. Schusterman Interests LLC acquired a new stake in shares of Heartflow in the 3rd quarter valued at $65,274,000. Vanguard Group Inc. bought a new position in shares of Heartflow in the 3rd quarter valued at $48,871,000. Finally, Capital International Investors acquired a new stake in Heartflow in the third quarter valued at about $43,671,000.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. Wells Fargo & Company initiated coverage on Heartflow in a research note on Wednesday, January 28th. They issued an "overweight" rating and a $38.00 price target on the stock. Stifel Nicolaus upped their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company a "buy" rating in a report on Thursday, November 13th. Canaccord Genuity Group raised their target price on shares of Heartflow from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a "sell (d)" rating on shares of Heartflow in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. boosted their price objective on Heartflow from $36.00 to $40.00 and gave the stock an "overweight" rating in a report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Heartflow currently has an average rating of "Moderate Buy" and a consensus price target of $38.50.
View Our Latest Stock Report on HTFL
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
